Assessment of cancer-related neuropathy and neuropathic pain.
Cancer-related neuropathic pain syndromes are common and serious complications of a patient's primary malignancy or its treatment, whether by surgery, radiation, or chemotherapy. They may compromise the patient's quality of life as well as their ability to receive effective treatment. In many patients, there may be more than one coexistent neuropathic pain syndrome, posing a diagnostic dilemma that, if unresolved, may result in the institution of therapies that are of limited scope or not targeted at the primary underlying pathophysiology. There is no single adequate diagnostic method that has been established to reliably diagnose or follow patients with cancer-related neuropathic pain syndromes. Clinical assessment of cancer-related neuropathic pain poses some important challenges diagnostically as well as in defining a clear and reliable endpoint assessment in controlled clinical trials. Many different approaches have been applied to the development of assessment or diagnostic tools. Careful review of these methods has been helpful in developing a clearer vision for the future design and refinement of more reliable tools, and more importantly, validation of the clinical utility as well as the reliability of such tools when employed as endpoints in clinical trials focused on prevention, mitigation, or treatment of cancer neuropathic pain.
Cleeland
Charles S
CS
University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Farrar
John T
JT
Hausheer
Frederick H
FH
D000970:Antineoplastic Agents / Q000009:adverse effects; D003943:Diagnostic Techniques, Neurological; D006801:Humans; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy; D009437:Neuralgia / Q000175:diagnosis* / Q000209:etiology*; D011795:Surveys and Questionnaires
D000970:Antineoplastic Agents